Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen
- 30 June 1995
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (6) , 876-881
- https://doi.org/10.1016/0959-8049(94)00459-5
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- In Vitro and In Vivo Effects of Cisplatin on the Generation of Lymphokine-Activated Killer CellsJNCI Journal of the National Cancer Institute, 1990
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Phase II study of recombinant leukocyte a interferon (rIFN-αA) in disseminated malignant melanomaCancer, 1984
- Results with methyl-CCNU and DTIC in metastatic melanomaCancer, 1977
- Combination Phase 1 -II Study of Imidazole Carboxamide (NCS 45388)Oncology, 1972